O
WX

OrbiMed’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

OrbiMed’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-31,500
Closed -$863K – 144
2013
Q3 		$863K Buy
+31,500
New +$746K 0.02% 125

Other funds holding WX

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
CI Investments Inc
CI Investments Inc Toronto, Ontario, Canada $20.6B AUM 29.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed's WX Position: Q4 2013 in Review

OrbiMed sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2013, closing a stake of 31,500 shares — an estimated $863K sold.

OrbiMed first reported a position in WX in Q3 2013 and held it in 1 quarter. The position peaked at $863K in Q3 2013. 164 funds tracked by Wall St. Rank hold WX as of Q4 2013.

  • OrbiMed reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2013 after selling out during the quarter.
  • OrbiMed sold 31,500 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2013, an estimated $863K.
  • OrbiMed first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 1 quarter.
  • OrbiMed's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $863K in Q3 2013.
  • 164 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2013.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.